Please login to the form below
melanoma
This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.
Vyriad inks immunotherapy alliance with Merck/Pfizer
The first and so far only therapy of this type to reach the market is Amgen’s melanoma therapy Imlygic (talimogene laherparepvec or T-Vec, approved by the FDA in 2015,
Latest news
-
BMS presses go on Nektar combo pivotal trials, despite data debate
The first phase III trial in melanoma is due to start in the third quarter. ... of the cancers under test - melanoma and RCC - even though the thresholds were met to advance into late-stage testing.
-
Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more
The phase I study will evaluate the benefits in patients who progressed on prior PD-1 inhibitor therapy with renal, bladder, melanoma and non-small cell lung cancer.
-
ACT immunotherapy cures terminal breast cancer patient
ACT has been shown to be effective in treating tumours with a high level of mutations such as melanoma, but has been less successful when tested in cancers with a lesser
-
Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline
in pancreatic cancer, as well as earlier-stage trials in other advanced solid tumours including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).
-
Another IO knockback as Tecentriq combo fails phase III trial
Despite the explanation, the result casts a shadow on Roche’s extensive plans for the Tecentriq/Cotellic combination, with trials ongoing or planned in other cancers including melanoma – with two pivotal
More from news
Approximately 76 fully matching, plus 277 partially matching documents found.
Latest Intelligence
-
Lighting the way
The independent review's final report emerged in October 2016, with potential implications for treatment access for a number of conditions, with myeloma, melanoma and dementia highlighted in the publication.
-
Managed Access Programmes: a powerful source of real-world insight
Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded
-
Managed Access Programmes: a powerful source of real-world insight
Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded
-
Deal Watch February 2016
The lead siDNA, DT01, has been tested in a phase I/II study in metastatic melanoma and Onxeo plans to investigate the potential of this approach in various solid tumours.
-
Pharma deals during July 2014
In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is ... FDA approved for late-stage melanoma.
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
-
Bruno Strigini leaves Merck & Co for Novartis
Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
-
Chris Bowden joins Agios
During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
-
Jonathan Dickinson joins Ariad from BMS
The drug made $786m worldwide during 2012 following approvals to treat adult patients with metastatic melanoma who have received prior therapy.
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Why patient education is important in oncology
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments ... Therefore, the Melanoma Patient Network Europe has a
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Immuno-oncology; bringing patients closer to treatment
Multi-stakeholder immuno-oncology experience. Blue Latitude Health has worked across a number of immunotherapies in melanoma, lung cancer, myeloma and acute lymphoblastic leukaemia.
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
A stumble, but not a fall – what’s next for Opdivo?
The immuno-oncology treatment won an accelerated FDA approval for metastatic melanoma in December 2014, and has since proved to be a thriving sensation.
More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.
Featured jobs
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
Subscribe to our email news alerts
- Moving annual total (MAT)
- Brexit rebels win vote on European Medicines Agency alignment
- MaxCyte gets green light for solid tumour cell therapy
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England to Vertex: come clean on Orkambi offer
- AstraZeneca joins Merck in Brexit stockpiling effort
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
